Abstract
Over the last half a century, there have been innumerable advances in our understanding of the human immune system. We now have a better understanding not only of the ways our innate and adaptive immune pathways interact to seek out and control infection and malignancy, but we are closer to understanding some of the control mechanisms behind tissue rejection. Organ allograft rejection, with consequent loss of graft function, remains one of the most challenging problems facing solid organ allotransplantation. Developments in therapeutic immunosuppression have enabled us to minimize rejection risk and improve the life expectancy and graft survival for many of our patients, but at a cost: the more intense the immunosuppression, typically the greater the infection risk. Ultimately, the field continues to work towards ways of achieving organ tolerance whereby both rejection risk and the threats of infection are minimized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Linden P. History of solid organ transplantation and organ donation. Crit Care Clin. 2009;25(1):165–84.
De Vito Dabbs A, Dauber JH, Hoffman LA. Rejection after organ transplantation: a historical review. Am J Crit Care. 2000;9(6):419–29.
Transplant Pioneers Recall Medical Milestone. NPR. December 20, 2004. Retrieved 20 Dec 2019.
Chen J, Li J, Wu Q. Maintenance of naïve CD8 T cells in nonagenarians by leptin, IGFBP3 and T3. Mech Ageing Dev. 2010;131(1):29–37.
Lim M, Kohli J, Blood R. Immunosuppression for kidney transplantation: where are we now and where are we going? Transplant Rev. 2017;31(1):10–7.
Cruse J, Lewis R, Wang H. Immunology guidebook. Amsterdam: Academic; 2004. p. 267–76.
DeWolf S, Sykes M. Alloimmune T cells in transplantation. J Clin Invest. 2017;127(7): 2473–81.
De Bruyn P, Van Gestel D, Ost P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? Curr Opin Oncol. 2019;31(2):54–64.
Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2015 annual data report: kidney. Am J Transplant. 2017;17(Suppl 1):21–116.
Witt CA, Gaut JP, Yusen RD, Byers DE, Iuppa JA, Bennett Bain K, Alexander Patterson G, Mohanakumar T, Trulock EP, Hachem RR. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant. 2013;32(10):1034–40. Epub 2013 Aug 13.
Zhang SY, Jouanguy E, Sancho-Shimizu V, et al. Human toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev. 2007;220(1):225–36.
Zhao H, Alam A, Soo AP, George AJT, Ma D. Ischemia-reperfusion injury reduces long term renal graft survival: mechanism and beyond. EBioMedicine. 2018;28:31–42.
Lu C, Penfield J, Kielar M, Vazquez M, Jeyarajah R. Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int. 1999;55(6):2157–68.
Villard J. The role of natural killer cells in human solid organ and tissue transplantation. J Innate Immun. 2011;3(4):395–402.
Benichou G, Yamada Y, Aoyama A, Madsen J. Natural killer cells in rejection and tolerance of solid organ allografts. Curr Opin Organ Transplant. 2011;16(1):47–53.
Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med. 2006;203(8):1851–8.
Surana N, Kasper K. Deciphering the tete-a-tete between the microbiota and the immune system. J Clin Invest. 2014;124(10):4197–203.
Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci. 1993;696:9–19.
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.
Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91(3): 423–33.
Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy. 1997;17(6):1148–56.
Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol. 1996;60(5):563.
Sam T, Gabardi S, Tichy EM. Risk evaluation and mitigation strategies: a focus on belatacept. Prog Transplant. 2013;23(1):64–70.
Nulojix. (webpage) Risk evaluation and mitigation strategy for increased risk of PTLD, predominantly involving the CNS, and PML with NULOJIX. Available from http://www.nulojix.com/hcp/rems.aspx?cm_mc_uid=03785373987414557419388&cm_mc_sid_51110000=1459792841
Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 2004;10(6):728–33.
Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909–19.
Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc. 2009;6(1):47–53.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Wolfe, C.R. (2021). Introduction to Immunosuppression, Tolerance, and Infection Risk. In: Morris, M.I., Kotton, C.N., Wolfe, C.R. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-25869-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-25869-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-25868-9
Online ISBN: 978-3-030-25869-6
eBook Packages: MedicineReference Module Medicine